Similarly, the association between DPP-4 inhibitors administration and increase risk of autoimmune diseases, including inflammatory bowel disease [25] and Hashimoto’s thyroiditis [26], was reported in some cohort studies. This evidence concerns the gene DPP4 and inflammatory bowel disease.